Open surgical and endovascular treatment of superior vena cava syndrome caused by nonmalignant disease  by Kalra, Manju et al.
Open surgical and endovascular treatment of
superior vena cava syndrome caused by
nonmalignant disease
Manju Kalra, MBBS,a Peter Gloviczki, MD,a James C. Andrews, MD,b Kenneth J. Cherry, Jr, MD,a
Thomas C. Bower, MD,a Jean M. Panneton, MD,a Haraldur Bjarnason, MD,b Audra A. Noel, MD,a
Cathy Schleck, BS,c William S. Harmsen, MS,c Linda G. Canton, RN, BSN,a and Peter C. Pairolero,
MD,a Rochester, Minn
Objectives:The purpose of this study was to evaluate the role of endovascular and open surgical reconstructions in patients
with superior vena cava (SVC) syndrome caused by nonmalignant disease.
Methods: Clinical data from 32 consecutive patients who underwent endovascular or open surgical reconstruction of
central veins because of symptomatic benign SVC syndrome betweenNovember 1983 and June 2001were retrospectively
reviewed.
Results: The study included 17 male and 15 female patients (mean age, 38 years; range, 5-69 years). Presenting symptoms
were head fullness (n 26), dyspnea or orthopnea (n 23), headache (n 17), or dizziness (n 11); physical signs were
head swelling (n 31), chest wall collateral vessels (n 29), facial cyanosis (n 18), or arm swelling (n 17). Etiologic
factors includedmediastinal fibrosis (n 19), indwelling catheter (n 8), idiopathic thrombosis (n 4), or post-surgery
(n  1). Two patients were heterozygous for factor V Leiden; 1 patient had antithrombin III deficiency. Twenty-nine
patients underwent surgical reconstruction with 31 bypass grafts: spiral saphenous vein (n 20), superficial femoral vein
(n  4), human allograft (n  1), or expanded polytetrafluoroethylene (ePTFE, n  6). Eleven patients underwent
percutaneous transluminal angioplasty or stenting; 3 primary and 8 secondary endovascular procedures were performed
to treat graft stenosis (n 7) or occlusion (n 1). There were no early deaths. Five early graft failures in 3 ePTFE grafts
and 2 bifurcated vein grafts (thrombosis, n  4; stenosis, n  1) were successfully treated with open surgical revision.
Over a mean follow-up of 5.6 years (range, 0.4-16.6 years) in surgical patients, 17 additional secondary interventions
were performed in 8 patients, 14 endovascular and 3 surgical. Primary, assisted primary, and secondary patency rates of
surgical bypass grafts were 63%, 79%, and 85%, respectively, at 1 year, and 53%, 68%, and 80%, respectively, at 5 years.
Graft patency was significantly higher in vein grafts compared with ePTFE grafts (P  .02). Mean follow-up after
percutaneous transluminal angioplasty or stenting was 3.1 years (range, 1 day–11.7 years). Twelve secondary endovas-
cular interventions were performed in 6 patients (primary group, 3 of 3; secondary group, 3 of 9 grafts in 8 patients) to
maintain patency in 11 of 12 reconstructions. Mean follow-up in the entire patient cohort was 5.3 years (range, 0.4-16.6
years). In 79% of patients symptoms had resolved or were significantly improved at last follow-up.
Conclusions: Surgical treatment of benign SVC syndrome is effective over the long term, with secondary endovascular
interventions to maintain graft patency. Straight spiral saphenous vein graft remains the conduit of choice for surgical
reconstruction, with results superior to those with bifurcated vein and ePTFE. Endovascular treatment is effective over
the short term, with frequent need for repeat interventions. It does not adversely affect future open surgical reconstruc-
tion and may prove to be a reasonable primary intervention in selected patients. Patients who are not suitable for or who
fail endovascular intervention merit open surgical reconstruction. (J Vasc Surg 2003;38:215-23.)
Benign disease is a rare cause of superior vena cava
(SVC) syndrome, accounting for only 22% of cases.1,2
About half of affected patients (11%) have mediastinal
fibrosis.3-5 However, the exponential increase in use of
indwelling central venous catheters and cardiac pacemakers
over the last two decades has resulted in more patients with
SVC obstruction of benign etiology. In this group of
relatively young patients with normal life expectancy, a
durable method of treatment is desirable. Traditional man-
agement is open surgery, with bypass grafting from the
innominate vein or jugular vein to the SVC or right atrial
appendage.6-15
Endovascular therapy with balloon angioplasty (percu-
taneous transluminal angioplasty [PTA]), and in recent
years with stenting of the SVC, has been performed with
increasing frequency.16-21 This is accepted as the mainstay
of treatment to relieve SVC obstruction due to malignant
disease, keeping in mind the short life expectancy of these
patients. The role of endovascular therapy in SVC syn-
drome of nonmalignant etiology is undecided, because
long-term durability of this method of treatment remains
to be assessed. The literature reports 90% to 100% initial
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success rates, with good short-term secondary patency rates
of up to 85% at 1 year in small series of patients.17,19,22-24
We evaluated the role of endovascular and surgical
reconstruction in contemporary management of SVC syn-
drome caused by nonmalignant disease. We assessed long-
term clinical results of surgical treatment, and feasibility of
and short-term outcome after endovascular interventions
performed to treat benign SVC syndrome at our institu-
tion.
PATIENTS AND METHODS
Clinical data for 32 consecutive patients with SVC
syndrome caused by nonmalignant disease treated at the
MayoClinic over 18 years fromNovember 1, 1983, to June
30, 2001, were retrospectively analyzed. Data collected
included details of preoperative clinical status, noninvasive
and invasive evaluation, operative and endovascular proce-
dures, post-procedure surveillance, early and late adjunc-
tive procedures, and clinical outcome during follow-up.
On the basis of venographic pattern of SVC obstruc-
tion, patients were classified into four groups with the
classification of Stanford and Doty.25 All surgical patients
with bypass grafts underwent imaging before discharge
from the hospital, and all patients had at least one return
visit at 3 to 6 months after surgery or endovascular treat-
ment. Patients with no return visit within the last 6 months
were contacted by telephone to determine follow-up clini-
cal status. Post-treatment clinical outcome was evaluated in
all patients and graded according to the classification
scheme proposed by the Subcommittee on Reporting Stan-
dards in Venous disease26: 3, complete relief of symp-
toms, 2, mild symptoms of chronic venous disease, 1,
clinical improvement, or 0, no clinical change.
Statistical analysis. Statistical analysis was performed
in the surgical group of 29 patients. In 2 patients who
underwent two bypass procedures sequentially, only the
first graft was included in the analysis. The Kaplan-Meier
method was used to estimate graft survival with respect to
patency for three end points: survival free of assisted pri-
mary patency, secondary patency, and any intervention to
treat occlusion.27 The date of operation was the starting
point of the analysis. For each analysis, grafts were classified
as patent or occluded, only on the basis of objective evi-
dence on radiologic imaging studies, ie, computed tomog-
raphy (CT), magnetic resonance imaging (MRI), or venog-
raphy. For the end point of loss of primary patency, a graft
requiring assistance to maintain patency (assisted primary)
was counted as an event on the date of assistance. For the
end point of intervention to treat occlusion, assistance to
maintain patency was also counted as an event. The 95%
confidence interval was calculated at 1-year, 3-year, and
5-year survival estimates. Univariate assessment of risk fac-
tors for each of the three survival end points was performed
with a log-rank test.28 P  .05 was considered statistically
significant.
Survival analyses were also performed to account for all
31 grafts in the 29 patients, with Cox proportional hazards
models, adjusting for correlated data between 2 grafts in
the 2 patients with multiple grafts. These results were
similar to those of the original analysis of 29 grafts (1 graft
per patient) and led to the same conclusions. Hence the
simpler analysis of 29 grafts is reported. Descriptive data,
however, include all 31 grafts for completeness. Statistical
analysis was not performed on data for the 3 patients who
underwent primary endovascular interventions (PTA with




Seventeen male patients and 15 female patients (medi-
an age, 38 years; range, 5-69 years) with SVC syndrome of
nonmalignant cause who underwent surgical or endovas-
cular intervention were included in the study. All patients
had persistent signs and symptoms of SVC obstruction
despite medical management and physical measures to de-
crease venous congestion of the head and neck. Median
duration of symptoms was 14 months (mean, 20 months;
range, 3-72 months). The most common symptoms of
SVC syndrome were head and neck fullness, and dyspnea
on exertion or orthopnea (Table I). The most frequently
encountered signs included head and neck swelling and
chest wall collateral vessels. One 5-year-old boy had signs of
SVC obstruction and severe protein-losing enteropathy
secondary to compromised drainage of the thoracic duct as
a result of high central venous pressure. At birth, he had
undergone excision of a mediastinal tumor (benign tera-
toma) along with a segment of SVC and right atrium.
Mediastinal fibrosis was the cause of SVC obstruction
in 19 patients (59%), and central venous thrombosis in 12
patients (38%) (Table II). PTA and stenting of the SVC had
been attempted in 9 patients elsewhere, before enrollment
in the present study, and was successful in 7 patients, with
subsequent reocclusion, and unsuccessful in 2 patients.
Two patients had undergone previous failed surgical SVC
reconstruction, ie, replacement of the SVC followed post-
Table I. Signs and symptoms of superior vena cava
syndrome of benign origin in 32 patients
No. of patients %
Symptom
Feeling of fullness in head or neck 26 81
Dyspnea on exertion or orthopnea 23 72
Headache 17 53
Dizziness or syncope 11 34
Visual problems 8 25
Cough 7 22
Nocturnal oxygen requirement 3 9
Proteinlosing enteropathy 1 3
Sign
Head and neck swelling 31 97
Large chest wall venous collateral vessels 29 91
Facial cyanosis 18 56
Arm swelling 17 53
Pleural effusion 2 6
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operatively by tight stenosis resistant to PTA in 1 patient,
and pericardial patch angioplasty of the SVC followed by a
right innominate vein to right atrium spiral vein graft in the
other patient. Risk factors included a history of deep venous
thrombosis (DVT) in 8 patients (25%), heterozygosity for
factor V Leiden in 2 patients, and antithrombin III defi-
ciency in 1 patient. Seven patients (22%) had hypertension,
3 patients (9%) had diabetes, and 14 patients (44%) were
smokers.
Preoperative evaluation
Preoperative evaluation included bilateral upper ex-
tremity venography in all patients. Thirty patients (94%)
underwent CT of the chest, and 7 patients (22%) under-
went MRI. Duplex ultrasound (US) scanning of the inter-
nal jugular veins was performed in 24 patients (75%). On
the basis of venographic findings, SVC obstruction was
classified as type I (90% stenosis of the SVC with ante-
grade azygos blood flow) in 3 patients (9%), type II (90%
SVC stenosis or occlusion with antegrade azygos blood
flow) in 5 patients (16%), type III (90% SVC stenosis or
occlusion with reversal of azygos blood flow) in 13 patients
(41%), and type IV (occlusion of SVC and major tributaries
including azygos veins) in 11 patients (34%).
Mediastinoscopy and biopsy was performed preopera-
tively in 9 patients with mediastinal fibrosis; thoracotomy
or thoracoscopy and biopsy was performed in 3 patients. In
all patients with mediastinal masses a lymph node biopsy
specimen was obtained intraoperatively before bypass graft-
ing. One patient with acute on chronic central line–related
thrombosis underwent thrombolytic therapy to provide
inflow into an internal jugular to right atrial appendage
bypass graft.
SVC reconstruction
Open surgery. The technique of autologous spiral
saphenous vein bypass grafting was as described previous-
ly.7,8,29 The saphenous vein is harvested and opened lon-
gitudinally, and valve leaflets are excised. The opened vein
is wrapped around a 32F or 36F polyethylene chest tube,
and the edges are stapled or sutured with 7.0 continuous
monofilament nonabsorbable suture, interrupting the su-
ture line every three-quarter turn. The length of saphenous
vein harvested to create a graft of sufficient length is deter-
mined according to the equation proposed by Chiu et al30
in their original experiments, l  RL/r, where r and l are
radius and length of saphenous vein, and R and L are radius
and length of the spiral vein graft.
Thirty-one bypass grafts were performed in 29 patients.
Reconstruction was performed with autologous spiral sa-
phenous vein grafts (SSVG) in 20 patients (65%), ie, 18
straight grafts and 2 bifurcated grafts (Table III). Superfi-
cial femoral vein (SFV) was the conduit in 4 patients, and
expanded externally supported polytetrafluoroethylene
(ePTFE, 10-16 mm diameter) in 6 patients. Human ilioca-
val vein was used in 1 patient with sclerosing cholangitis
and mediastinitis, who underwent concomitant orthotopic
liver transplantation. The grafts originated from the inter-
nal jugular vein (n  17) or innominate vein (n  14) and
were anastomosed centrally to the SVC (n  18) or right
atrial appendage (n  13). All grafts were imaged before
patients were discharged. At discharge, 26 of 29 patients
were receiving oral anticoagulation therapy with warfarin
sodium (target international normalized ratio, 2 to 3).
Two patients received 2 grafts sequentially. One patient
required straight SSVGs from each innominate vein to the
right atrial appendage because of persistent symptoms after
placement of the first graft (Fig 1). Both grafts were patent
at last follow-up 41⁄2 years postoperatively. In the other
patient a thrombosed ePTFE graft was replaced with an
SSVG graft at 1 year and remains patent after 2 years. Only
the first graft in each of these patients was included in the
statistical analysis.
Endovascular treatment. Endovascular interventions
were performed in 11 patients. Three patients with type II
SVC lesions due to histoplasmosis were treated primarily
with PTA and stenting of the SVC. Palmaz stents (Palmaz
308; Cordis, Johnson & Johnson, Warren, NJ) were used
Table II. Cause of benign superior vena cava syndrome
in 32 patients
No. of patients %








Post–radiation therapy 1 3




Pacemaker wires 2 6
Ventriculoatrial shunt 1 3
Hypercoagulable state 1 3
Idiopathic 3 9
Surgical excision 1 3
Total 32 100
Table III. Graft material for 31 grafts in 29 patients with
surgical reconstruction*
No. of patients %
Autologous vein 24 77
Spiral saphenous vein 20 65
Straight graft 17 55
Bifurcated graft 2 6
Straight graft plus reimplantation
opposite innominate vein
1 3
Superficial femoral vein 4 13
Reversed vein graft 3 10
Spiral vein graft 1 3
Iliocaval allograft 1 3
Expanded polytetrafluroethylene 6 19
Total 31 100
*Two patients received 2 bypass grafts each.
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in 2 patients, and a 12 mm Wallstent (Boston Scientific,
Medi-Tech, Natick, Mass) was used in 1 patient. Endovas-
cular interventions were also performed to maintain pa-
tency of 9 grafts in 8 patients in the open surgical group.
These included PTA alone in 4 grafts, and PTA plus stent-
ing in 5 grafts (10-12 mm Wallstents, n  4; Palmaz 308
stent, n  1). Patients received oral anticoagulants post-
intervention for a minimum of 3 months.
Initial diagnostic venography was performed with si-
multaneous injection of contrast medium in bilateral super-
ficial arm veins. The interventions were performed with a
standard transjugular or transfemoral venous Seldinger
technique, insertion of a 7 to 10 mm sheath, and crossing
the stenotic lesion in the SVC with a guide wire and 5F
catheter. Pressure gradient across the lesion was measured
before and after intervention to ensure a satisfactory result.
Balloon dilation was performed with 10 to 14 mm balloon
catheters, and was followed by deployment of the chosen
stent across the lesion in patients with residual stenosis.
Early results
Mortality and morbidity. There were no in-hospital
or early (30 days) deaths. In 2 patients in whom the SFV
was harvested, acute DVT of the popliteal vein developed.
Amediastinal hematoma in 1 patient compressed the SSVG
and required evacuation. In a fourth patient, with concom-
itant excision of a large retrosternal goiter, bilateral vocal
cord paralysis developed, and prolonged ventilator depen-
dence necessitated tracheostomy.
Patency of reconstruction. Five early repeat interven-
tions were performed to maintain graft patency. Three
ePTFE grafts demonstrated thromboses in the early post-
operative period. All underwent thrombectomy, and patch
angioplasty of the proximal anastomosis was performed in 1
graft. Both bifurcated SSVG grafts demonstrated early
complications. Partial thrombosis of 1 graft was successfully
treated with thrombectomy and revision of the side limb
anastomosis. Thrombosis of the side limb of the other graft
was treated with thrombectomy and reimplantation; how-
ever, this graft demonstrated early recurrent thrombosis.
All grafts, except one limb of a bifurcated graft, were patent
at discharge. Nonsignificant (50%) stenosis was noted in
5 grafts at postoperative imaging before discharge. Thirty-
day primary patency was 84%, assisted primary patency was
87%, and secondary patency was 100%. In the 3 patients
who underwent primary PTA and stenting of the SVC,
primary patency was 100% at 30 days.
Late results
Mortality. Mean clinical follow-up in the surgical
group was 5.6 years (range, 0.4-16.6 years). Follow-up
after endovascular intervention in 11 patients (3 primary
and 8 secondary interventions in bypass grafts) was 3.1
years (range, 1 day–11.7 years). During follow-up 3 pa-
tients died of unrelated causes: 1 patient died of broncho-
genic carcinoma 9 years after SSVG bypass to treat central
line–related thrombosis with complete relief from symp-
toms; 1 patient died of unknown cause after remaining
asymptomatic for more than 8 years after SSVG because of
pacemaker wire–related thrombosis; and 1 patient died of
long-standing complications related to tuberculous perito-
nitis 17 months after placement of an ePTFE graft to treat
central line–related thrombosis. Four patients were lost to
follow-up at 6, 19, 24, and 70 months, respectively, after
surgical treatment.
Patency of reconstruction. Open surgery. Postop-
erative graft surveillance with venography was performed at
3 to 6months, and then at 9 to 12months in most patients.
Thereafter, grafts were imaged noninvasively with CT (n
33) or MRI (n  5); venography was reserved for patients
with recurrent symptoms or known stenosis. In later years
of the study, the second venography was sometimes re-
placed with CT or MRI. On 68 late postoperative
venograms, mild or moderate stenosis was found in 12
grafts, severe stenosis in 11 grafts or limbs, and occlusion in
1 graft. DuplexUS scanning was performed in 24 instances;
graft patency was indirectly inferred from the flow pattern
in the internal jugular vein because the graft in the medias-
tinum was not directly visualized with this method. In no
instance was final patency for statistical analysis based on a
duplex US scan. On one occasion graft occlusion was
confirmed by ultrasound alone in a patient in whom no
further intervention was planned.
Fig 1. A,Venogram 10months after placement of left innominate
vein to right atrial appendage spiral saphenous vein graft in a
46-year-old man with mediastinal fibrosis shows severe stenosis
(arrow) at the proximal anastomosis. B, Venogram 6 months after
Wallstent (arrow) placement confirms widely patent stent and
graft. C, Venogram of right to left internal jugular crossover graft
(arrow) performed 16 months later because of persistent right arm
and neck swelling. D, Early occlusion of crossover graft at 2
months. E, Venogram 6 months after placement of right innomi-
nate vein to right atrial appendage spiral saphenous vein graft
shows external compression of the distal graft (arrow). F,
Venogram obtained afterWallstent (arrow) placement. Both grafts
remain patent 4 years later.
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Mean duration of follow-up for graft patency (based on
last imaging) was 3.2 years (range, 4 days–10 years). Dur-
ing follow-up 9 grafts required secondary interventions
(high-grade stenosis, n  7; partial thrombosis, n  1;
occlusion, n  1). Six of 7 high-grade stenoses occurred
within the first year (between 3 and 10 months) after
operation, and 1 occurred at 37 months. Three of these
patients had nonsignificant stenosis at discharge from the
hospital. The 7 stenosed vein grafts (6 SSVG, 1 SFV)
underwent endovascular interventions (PTA, n  3; Wall-
stent, n  4). In all but 1 patient high-grade stenosis was
accompanied by recurrence of symptoms. Thrombolysis
and PTA of the internal jugular vein reestablished patency
in the partially thrombosed ePTFE graft. The occluded
ePTFE graft was replaced with SSVG.
Five grafts eventually occluded during follow-up
(ePTFE, n 3; SSVG, n 1; SFV, n 1). Both vein grafts
were repeat surgical reconstructions in patients with failed
surgical bypass grafts before enrollment in this study, and
no further intervention was attempted. One occluded
ePTFE graft was replaced with an SSVG, which remains
patent at 2 years.
One-year, 3-year, and 5-year cumulative primary pa-
tency rates for 29 surgical grafts were 63% (95% confidence
interval [CI], 48-85), 53% (95% CI, 36-78), and 53% (95%
CI, 32-78); assisted primary patency rates were 79% (95%
CI, 64-95), 68% (95% CI, 51-90), and 68% (95% CI,
48-90); and secondary patency rates were 85% (95% CI,
72-100), 80% (95% CI, 64-98), and 80% (95% CI, 61-98)
(Fig 2,A). Patency rates were significantly higher for SSVG
compared with ePTFE grafts: 1-year and 4-year cumulative
primary patency rates were 67% (95% CI, 49-91) and 67%
(95% CI, 42-91) versus 50% (95% CI, 23-100) and 17%
(95% CI, 17-100), respectively (P  .02). Secondary pa-
tency rates were 90% (95% CI, 78-100) and 90% (95% CI,
73-100) versus 67% (95% CI, 38-100) and 50% (95% CI,
16-100), respectively (P  .02) (Fig 2, B).
Endovascular treatment. Mean duration of follow-up
for patency (based on last imaging) was 2 years (range, 1
day–10 years). Venography was performed in 11 patients
during follow-up, 5 for surveillance and 6 because of recur-
rent symptoms. Secondary interventions were performed in
all 3 patients treated primarily with PTA and stenting: 1
intervention in 2 patients and 4 interventions in 1 patient
(Fig 3). All secondary interventions were performed be-
cause of recurrent stenosis associated with recurrent symp-
toms. One patient chose to undergo SSVG at another
institution 19 months after initial stenting rather than
repeated endovascular interventions. The fifth intervention
in a 38-year-old man was complicated by pericardial tam-
ponade, which responded promptly to pericardial drainage.
In the secondary endovascular intervention group (8
patients), 5 of 9 grafts were patent at last follow-up without
further intervention; 1 graft became occluded, and the
remaining 3 grafts required further endovascular interven-
tions (1, 2, and 4 interventions, respectively).
Outcome
Mean duration of follow-up for clinical outcome in all
patients was 5.6 years (range, 0.4-16.6 years). At last fol-
low-up or death, symptoms in 79% (95% CI, 60-92) of
patients had resolved or were significantly improved (Fig
4). All patients with occluded grafts had recurrent symp-
toms. Only 1 patient, with the factor V Leiden gene and a
patent graft, had no improvement of symptoms.
Risk factor analysis
Univariate analysis identified only ePTFE graft as a
factor associated with poor primary and secondary graft
patency (Fig 2, B). Other preoperative factors, ie, gender,
age, type and cause of SVC obstruction, previous PTA or
stenting, pressure gradient across the lesion, and intraoper-
ative graft blood flow measurements, had no significant
effect on outcome relative to graft patency.
DISCUSSION
Endovascular intervention with PTA and stenting is the
treatment of choice for patients with SVC syndrome due to
malignant disease with symptoms unresponsive to radiation
therapy and chemotherapy.17,21-13,31 Surgical intervention
has been the mainstay of treatment of benign SVC syn-
drome since the first SVC bypass graft half a century ago,5
with good long-term results. However, given that SVC
syndrome of nonmalignant origin accounts for only a small
proportion of cases, the total experience remains small.
Doty et al11 reported excellent long-term patency and
clinical results of SSVG in 16 patients. We have reported
our experience with bypass grafting in 19 patients.10 Suc-
cess with PTA and stenting in malignant SVC syndrome,
and increasing sophistication of endovascular techniques
and devices have raised the question of whether endovas-
cular treatment can replace surgery as the primary method
of management of benign SVC syndrome as well.22,23,32
This question is especially relevant today, with the escalat-
ing incidence of iatrogenic thrombosis of the SVC.
Surgical reconstruction of the SVC caused by benign
disease has been associated with excellent long-term re-
sults.6-9,11,12 Although the first reconstructions were per-
formed with SFV,5 since the description of the technique of
spiraling the saphenous vein by Chiu et al30 the SSVG has
been the most popular conduit. Doty et al6 first adopted
the technique, and in 1982 reported excellent graft patency
and freedom from symptoms. Their larger experience re-
ported in 1999, consisting of 16 SSVGs placed to treat
benign SVC syndrome, documented 88% long-term graft
patency and excellent clinical results at a mean follow-up of
10.9 years.11 The results of the present series confirm these
results, with 90% long-term patency in the 23 vein grafts
(SSVG, SFV, and allograft iliac vein). SSVG has been our
preferred conduit of choice. Straight SSVG is associated
with the most rewarding results; concomitant bilateral re-
constructions attempted early in our experience resulted in
early and late complications. We have since shied from
bilateral reconstructions and found that collateralization
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Fig 2. A, Cumulative primary, assisted primary, and secondary graft patency after open surgical bypass in 29 patients.
SEM  10% for all time points. B, Cumulative secondary patency after placement of 23 vein grafts and 6 expanded
polytetrafluoroethylene (ePTFE) bypass grafts to treat superior vena cava obstruction. Dotted line represents SEM 
10%.
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across the midline is adequate to decompress both sides
with a single graft in most patients.
The SFV is a good second choice for graft conduit, and
others have performed SVC reconstruction with
SFV.5,13,33 Concerns about distal thrombosis at the harvest
site and chronic venous insufficiency remain; DVT devel-
oped in 2 of 4 of our patients at the distal SFV and popliteal
vein, with long-term sequelae in one. Similar experience
has been reported by others.33 Clagett et al,34 in addition
to reporting 7 cases of major venous reconstruction (2 to
treat SVC syndrome) with SFV have the largest experience
with harvesting SFV for arterial reconstructions. Mid-term
follow-up in 61 patients revealed only mild signs of chronic
venous insufficiency in fewer than a third of patients, de-
spite evidence of outflow obstruction and mild reflux on
noninvasive venous evaluation.35 These results, however,
may not be directly applicable to the present group of
patients with SVC occlusion, especially that caused by
spontaneous or catheter-induced thrombosis. Nonetheless,
it is the logical conduit in patients with unavailable or
inadequate saphenous vein.
Although graft patency and clinical results were signif-
icantly poorer with ePTFE compared with vein in the
present series, it remains the best prosthetic material for use
in the venous system. Wisselink et al15 reported 100%
patency at 1 year for ePTFE bypass grafts placed to treat
central vein occlusion in 6 patients receiving hemodialysis.
A brachial arteriovenous fistula for dialysis present preop-
eratively in 5 of these patients may have contributed to the
excellent patency by augmenting graft blood flow. We have
documented better results with short, large-diameter
ePTFE bypass grafts for iliocaval reconstruction in the
setting of both benign and malignant disease.8 Dartevelle
et al36 and Magnan et al14 reported excellent patency with
ePTFE reconstruction of the SVC confined to the medias-
tinum after resection of malignant tumors. Five of 6 ePTFE
grafts in the present series originated in the neck, and the
small size of the internal jugular vein precluded use of
large-diameter grafts.
All high-grade graft stenoses occurred within the first
year postoperatively, and half of these were mild stenosis
present on the first postoperative surveillance venogram.
Regardless of the treatment method, the discovery of all
stenoses was accompanied by recurrence of symptoms ex-
cept in one patient. Although graft patency cannot be
automatically inferred from freedom from symptoms, on
the basis of these data, imaging after the first year need be
performed only in patients with symptoms or in patients
without symptoms but with known nonsignificant stenosis.
Similar views have been expressed by Doty et al.11
Open surgery has been the primary method of treat-
ment of symptomatic SVC obstruction of nonmalignant
etiology origin at our institution since the mid-1980s, with
PTA and stenting used secondarily to maintain patency of
vein grafts. Encouraging results with these endovascular
interventions over the last decade prompted us to use
primarily PTA or stenting in selected patients in the last few
years. Initial attempts at treating benign SVC syndrome
with endovascular means involved PTA alone, with early
recurrent stenosis caused by elastic recoil or compression
from surrounding fibrosis.37-39 In the early 1990s, occa-
sional cases of stent deployment to treat pacemaker wire–
induced thrombosis were reported, but repeated interven-
tions were required to maintain patency in the short
term.18,20,24,40-45 Early experience was with Gianturco Z
stents, which were subsequently modified by Rosch et al43
to create a multibody design that minimized stent migra-
tion. Availability of the more flexibleWallstents and Palmaz
stents in larger sizes added to the versatility of endovascular
treatment. In 1996 Dondelinger and Trotteur46 presented
a series of 20 patients with stents with a secondary patency
rate of 80% after mean follow-up of 16 months. Qanaldi et
al19 reported 12 patients treated with Wallstents; one
symptomatic recurrence occurred at 2 months over mean
follow-up of 11 months. All 3 patients in our series treated
primarily with PTA and stenting required at least one repeat
intervention. Despite excellent early success and prompt
relief of symptoms, the need for repeated interventions
makes acceptance of this method of treatment difficult in
this group of young, otherwise healthy patients. Longer
Fig 3. A, Venogram shows type II superior vena cava obstruction
(arrow) due to mediastinal fibrosis in a 38-year-old man. Success-
ful placement of a Palmaz stent resulted in immediate resolution of
symptoms. B, Venogram 14 months after stent palcement shows
high-grade stenosis of the left innominate vein proximal to the
stent. This was successfully treated with balloon angioplasty. C,
Venogram 8months later shows recurrence of stenosis (arrow).D,
Venogram after balloon angioplasty to treat stenosis of left innom-
inate vein and stent shows widely patent stent. Patient has under-
gone two additional balloon angioplasty procedures over 10
months to maintain patency.
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follow-up in a larger number of patients is required to
address the suitability of endovascular treatment as a per-
manent solution for benign SVC syndrome.
Surgical treatment of benign SVC syndrome is effective
over the long term, with secondary endovascular interven-
tions to maintain graft patency. Straight SSVG remains the
conduit of choice for surgical reconstruction, with results
superior to bifurcated vein and ePTFE. Endovascular treat-
ment is effective in the short term, with frequent need for
repeat interventions. It does not adversely affect future
open surgical reconstruction, and may prove to be a rea-
sonable primary therapeutic intervention in selected pa-
tients with suitable anatomy. Patients who are not suitable
for or who fail endovascular intervention merit open surgi-
cal reconstruction.
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